Detalhe da pesquisa
1.
Genomic landscape of non-small cell lung cancer in smokers and never-smokers.
Cell
; 150(6): 1121-34, 2012 Sep 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-22980976
2.
Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study.
Lancet Oncol
; 22(9): 1290-1300, 2021 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-34339623
3.
Efficacy of Neratinib Plus Capecitabine in the Subgroup of Patients with Central Nervous System Involvement from the NALA Trial.
Oncologist
; 26(8): e1327-e1338, 2021 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-34028126
4.
Mutation profile differences in younger and older patients with advanced breast cancer using circulating tumor DNA (ctDNA).
Breast Cancer Res Treat
; 185(3): 639-646, 2021 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-33219484
5.
The efficacy and safety of enzalutamide with trastuzumab in patients with HER2+ and androgen receptor-positive metastatic or locally advanced breast cancer.
Breast Cancer Res Treat
; 187(1): 155-165, 2021 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-33591468
6.
Neratinib + capecitabine sustains health-related quality of life in patients with HER2-positive metastatic breast cancer and ≥ 2 prior HER2-directed regimens.
Breast Cancer Res Treat
; 188(2): 449-458, 2021 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-33909203
7.
Immunogenomic profiling and pathological response results from a clinical trial of docetaxel and carboplatin in triple-negative breast cancer.
Breast Cancer Res Treat
; 189(1): 187-202, 2021 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-34173924
8.
Chemotherapy-related amenorrhea (CRA) after adjuvant ado-trastuzumab emtansine (T-DM1) compared to paclitaxel in combination with trastuzumab (TH) (TBCRC033: ATEMPT Trial).
Breast Cancer Res Treat
; 189(1): 103-110, 2021 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-34120223
9.
Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study.
Lancet Oncol
; 20(4): 518-530, 2019 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-30857956
10.
Breast Cancer, HER2 Mutations, and Overcoming Drug Resistance.
N Engl J Med
; 385(13): 1241-1243, 2021 Sep 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-34551235
11.
Retrospective Analysis of Treatment Patterns and Effectiveness of Palbociclib and Subsequent Regimens in Metastatic Breast Cancer.
J Natl Compr Canc Netw
; 17(2): 141-147, 2019 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-30787127
12.
Biophysical Evidence for Intrinsic Disorder in the C-terminal Tails of the Epidermal Growth Factor Receptor (EGFR) and HER3 Receptor Tyrosine Kinases.
J Biol Chem
; 292(2): 597-610, 2017 Jan 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-27872189
13.
Evaluation of [89Zr]trastuzumab-PET/CT in differentiating HER2-positive from HER2-negative breast cancer.
Breast Cancer Res Treat
; 169(3): 523-530, 2018 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-29442264
14.
HER2 missense mutations have distinct effects on oncogenic signaling and migration.
Proc Natl Acad Sci U S A
; 112(45): E6205-14, 2015 Nov 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-26508629
15.
Efficient sortase-mediated N-terminal labeling of TEV protease cleaved recombinant proteins.
Anal Biochem
; 521: 55-58, 2017 03 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-28088451
16.
Nonamplification ERBB2 genomic alterations in 5605 cases of recurrent and metastatic breast cancer: An emerging opportunity for anti-HER2 targeted therapies.
Cancer
; 122(17): 2654-62, 2016 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27284958
17.
DGIdb: mining the druggable genome.
Nat Methods
; 10(12): 1209-10, 2013 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-24122041
18.
Statistically identifying tumor suppressors and oncogenes from pan-cancer genome-sequencing data.
Bioinformatics
; 31(22): 3561-8, 2015 Nov 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-26209800
19.
Prognostic and Predictive Biomarkers of Endocrine Responsiveness for Estrogen Receptor Positive Breast Cancer.
Adv Exp Med Biol
; 882: 125-54, 2016.
Artigo
em Inglês
| MEDLINE | ID: mdl-26987533
20.
HER2-Mutated Breast Cancer Responds to Treatment With Single-Agent Neratinib, a Second-Generation HER2/EGFR Tyrosine Kinase Inhibitor.
J Natl Compr Canc Netw
; 13(9): 1061-4, 2015 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-26358790